Vasopressin Antagonists in Physiology and Disease

Textbook of Nephro-Endocrinology

Volumn , Issue , 2009, Pages 249-260

  Berl, Tomas ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882461743     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373870-7.00018-1     Document Type: Chapter

References (109)

1. Abraham W.T., Shamshirsaz A.A., McFann K., Oren R.M., Schrier R.W. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006, 47:1615-1621.
2. Adrogue H.J., Madias N.E. Hyponatremia. N Engl J Med 2000, 342:1581-1589.
3. Anderson R.J., Chung H.M., Kluge R., Schrier R.W. Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin. Ann Intern Med 1985, 102:164-168.
4. Ando Y., Jacobson H.R., Breyer M.D. Phorbol ester and A23187 have additive but mechanistically separate effects on vasopressin action in rabbit collecting tubule. J Clin Invest 1988, 81:1578-1584.
5. Anger M.S., Shanley P., Mansour J., Berl T. Effects of lithium on cAMP generation in cultured rat inner medullary collecting tubule cells. Kidney Int 1990, 37:1211-1218.
6. Baton T., Gavira M., Battle D. Prevalance, pathogenesis and treatment of renal dysfunction associated with chronic lithium therapy. Ann Intern Med 1987, 79:679.
7. Baylis P.H., Heath D.A. Water disturbances in patients treated with oral lithium carbonate. Ann Intern Med 1978, 88:607-609.
8. Berl T. The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat. Kidney Int 1987, 31:1065-1071.
9. Berl T., Schrier R.W. Mechanism of effect of prostaglandin E 1 on renal water excretion. J Clin Invest 1973, 52:463-471.
10. Berl T., Cadnapaphornchai P., Harbottle J.A., Schrier R.W. Mechanism of suppression of vasopressin during alpha-adrenergic stimulation with norepinephrine. J Clin Invest 1974, 53:219-227.
11. Berl T., Raz A., Wald H., Horowitz J., Czaczkes W. Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 1977, 232:F529-F537.
12. Berl T., Linas S.L., Aisenbrey G.A., Anderson R.J. On the mechanism of polyuria in potassium depletion. The role of polydipsia. J Clin Invest 1977, 60:620-625.
13. Bichet D.G. Nephrogenic and central diabetes insipidus. Diseases of the kidney and urinary tract 2007, Lippincott Williams & Wilkins, Philadelphia. 8th edn. R.W. Schrier (Ed.).
14. Bichet D., Szatalowicz V., Chaimovitz C., Schrier R.W. Role of vasopressin in abnormal water excretion in cirrhotic patients. Ann Intern Med 1982, 96:413-417.
15. Bosch J., Garcia-Pagan J. The splanchnic circulation in cirrhosis. Ascites and renal dysfunction in liver disease 2005, 156-163. Blackwell Publishing, Oxford. P. Gines, V. Arroyo, J. Rodes, R.W. Schrier (Eds.).
16. Chen Y.C., Cadnapaphornchai M.A., Yang J., et al. Nonosmotic release of vasopressin and renal aquaporins in impaired urinary dilution in hypothyroidism. Am J Physiol 2005, 289:F672-F678.
17. Chen Y.C., Cadnapaphornchai M.A., Summer S.N., et al. Molecular mechanisms of impaired urinary concentrating ability in glucocorticoid-deficient rats. J Am Soc Nephrol 2005, 16:2864-2871.
18. Christensen S., Kusano E., Yusufi A.N., Murayama N., Dousa T.P. Pathogenesis of nephrogenic diabetes insipidus due to chronic administration of lithium in rats. J Clin Invest 1985, 75:1869-1879.
19. Cogan E., Abramow M. Inhibition by lithium of the hydroosmotic action of vasopressin in the isolated perfused cortical collecting tubule of the rabbit. J Clin Invest 1986, 77:1507-1514.
20. Costello-Boerrigter L.C., Smith W.B., Boerrigter G., et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol 2006, 290:F273-F278.
21. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001, 138:18-21.
22. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001, 110:582-584.
23. Decaux G., Vandergheynst F., Bouko Y., Parma J., Vassart G., Vilain C. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007, 18:606-612.
24. Dousa T.P. Interaction of lithium with vasopressin-sensitive cyclic AMP system of human renal medulla. Endocrinology 1974, 95:1359-1366.
25. Du Vigneaud V. Hormones of the posterior pituitary gland: oxytocin and vasopressin. The Harvey Lectures 1956, 1954-1955. Academic Press, New York. V. Du Vigneaud, R.J. Bing, J.L. Oncley (Eds.).
26. Dunn F.L., Brennan T.J., Nelson A.E., Robertson G.L. The role of blood osmolality and volume in regulating vasopressin secretion in the rat. J Clin Invest 1973, 52:3212-3219.
27. Earm J.H., Christensen B.M., Frokiaer J., et al. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol 1998, 9:2181-2193.
28. Edwards R.M., Stack E.J., Pullen M., Nambi P. Endothelin inhibits vasopressin action in rat inner medullary collecting duct via the ETB receptor. J Pharmacol Exp Ther 1993, 267:1028-1033.
29. Feldman B.J., Rosenthal S.M., Vargas G.A., et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005, 352:1884-1890.
30. Finn A.L., Handler J.S., Orloff J. Relation between toad bladder potassium content and permeability response to vasopressin. Am J Physiol 1966, 210:1279-1284.
31. Forrest J.N., Cohen A.D., Torretti J., Himmelhoch J.M., Epstein F.H. On the mechanism of lithium-induced diabetes insipidus in man and the rat. J Clin Invest 1974, 53:1115-1123.
32. Fujisawa G., Ishikawa S., Tsuboi Y., Okada K., Saito T. Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats. Kidney Int 1993, 44:19-23.
33. Gauer O.H., Henry J.P. Neurohormonal control of plasma volume. Int Rev Physiol 1976, 9:145-190.
34. Geelen G., Greenleaf J.E., Keil L.C. Drinking-induced plasma vasopressin and norepinephrine changes in dehydrated humans. J Clin Endocrinol Metab 1996, 81:2131-2135.
35. Gerbes A.L., Gulberg V., Gines P., et al. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003, 124:933-939.
36. Ghali J.K., Koren M.J., Taylor J.R., et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006, 91:2145-2152.
37. Gheorghiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. J Am Med Assoc 1984, 291:1963-1971.
38. Gheorghiade M., Niazi I., Ouyang J., et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690-2696.
39. Gheorghiade M., Konstam M.A., Burnett J.C., et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. J Am Med Assoc 2007, 297:1332-1343.
40. Gines A., Escorsell A., Gines P., et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105:229-236.
41. Goldberg H., Clayman P., Skorecki K. Mechanism of Li inhibition of vasopressin-sensitive adenylate cyclase in cultured renal epithelial cells. Am J Physiol 1988, 255:F995-1002.
42. Goldsmith S.R., Cowley A.W., Francis G.S., Cohn J.N. Effect of increased intracardiac and arterial pressure on plasma vasopressin in humans. Am J Physiol 1984, 246:H647-H651.
43. Greenberg A., Verbalis J.G. Vasopressin receptor antagonists. Kidney Int 2006, 69:2124-2130.
44. Gutsche H.U., Peterson L.N., Levine D.Z. In vivo evidence of impaired solute transport by the thick ascending limb in potassium-depleted rats. J Clin Invest 1984, 73:908-916.
45. Guyader D., Patat A., Ellis-Grosse E.J., Orczyk G.P. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 2002, 36:1197-1205.
46. Helderman J.H., Vestal R.E., Rowe J.W., Tobin J.D., Andres R., Robertson G.L. The response of arginine vasopressin to intravenous ethanol and hypertonic saline in man: the impact of aging. J Gerontol 1978, 33:39-47.
47. Hoorn E.J., Lindemans J., Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006, 21:70-76.
48. Inoue T., Ohnishi A., Matsuo A., et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis. Clin Pharmacol Ther 1998, 63:561-570.
49. Ishikawa S., Schrier R.W. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats. Kidney Int 1982, 22:587-593.
50. Kim J.K., Summer S.N., Berl T. The cyclic AMP system in the inner medullary collecting duct of the potassium-depleted rat. Kidney Int 1984, 26:384-391.
51. Kinter L.B., Ilson B.E., Caltabianol S. Antidiuretic hormone antagonists in humans: are there predictors?. Vasopressin Third International Vasopressin Conference 1991, 321-329. John Libbey Eurotext, Paris. S. Jard, R. Jamison (Eds.).
52. Kleeman C.R., Rubini M.E., Lamdin E., Epstein F.H. Studies on alcohol diuresis. II. The evaluation of ethyl alcohol as an inhibitor of the neurohypophysis. J Clin Invest 1955, 34:448-455.
53. Kohan D.E., Hughes A.K. Autocrine role of endothelin in rat IMCD: inhibition of AVP-induced cAMP accumulation. Am J Physiol 1993, 265:F126-F129.
54. Konstam M.A., Gheorghiade M., Burnett J.C., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. J Am Med Assoc 2007, 297:1319-1331.
55. Lee W.H., Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986, 73:257-267.
56. Levi M., Peterson L., Berl T. Mechanism of concentrating defect in hypercalcemia. Role of polydipsia and prostaglandins. Kidney Int 1983, 23:489-497.
57. Lindheimer M.D., Davison J.M. Osmoregulation, the secretion of arginine vasopressin and its metabolism during pregnancy. Eur J Endocrinol 1995, 132:133-143.
58. Macion-Dazard R., Callahan N., Xu Z., Wu N., Thibonnier M., Shoham M. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor. J Pharmacol Exp Ther 2006, 316:564-571.
59. Manning M., Sawyer W.H. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 1989, 114:617-632.
60. Marples D., Christensen S., Christensen E.I., Ottosen P.D., Nielsen S. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla. J Clin Invest. 1995, 95:1838-1845.
61. Marples D., Frokiaer J., Dorup J., Knepper M.A., Nielsen S. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 1996, 97:1960-1968.
62. Martin P.Y., Abraham W.T., Lieming X., et al. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure. J Am Soc Nephrol 1999, 10:2165-2170.
63. Miller M. Role of endogenous opioids in neurohypophysial function of man. J Clin Endocrinol Metab 1980, 50:1016-1020.
64. Nielsen S., Terris J., Andersen D., et al. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci USA 1997, 94:5450-5455.
65. Nielsen J., Kwon T.H., Praetorius J., et al. Segment-specific ENaC downregulation in kidney of rats with lithium-induced NDI. Am J Physiol 2003, 285:F1198-F1209.
66. Nielson S., Knepper M.A., Kwon T., Frokiaer J. Regulation of water balance: urine concentration and dilution. Diseases of the kidney and urinary tract 2007, Lippincott Williams & Wilkins, Philadelphia. 8th edn. R.W. Schrier (Ed.).
67. Ohnishi A., Orita Y., Okahara R., et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993, 92:2653-2659.
68. Oiso Y., Iwasaki Y., Kondo K., Takatsuki K., Tomita A. Effect of the opioid kappa-receptor agonist U50488H on the secretion of arginine vasopressin. Study on the mechanism of U50488H-induced diuresis. Neuroendocrinology 1988, 48:658-662.
69. Omachi R.S., Robbie D.E., Handler J.S., Orloff J. Effects of ADH and other agents on cyclic AMP accumulation in toad bladder epithelium. Am J Physiol 1974, 226:1152-1157.
70. Peterson L.N. Vitamin D-induced chronic hypercalcemia inhibits thick ascending limb NaCl reabsorption in vivo. Am J Physiol 1990, 259:F122-F129.
71. Reid I.A., Ahn J.N., Trinh T., Shackelford R., Weintraub M., Keil L.C. Mechanism of suppression of vasopressin and adrenocorticotropic hormone secretion by clonidine in anesthetized dogs. J Pharmacol Exp Ther 1984, 229:1-8.
72. Relman A.S., Schwartz W.B. The kidney in potassium depletion. Am J Med 1958, 24:764-773.
73. Robertson G.L. The regulation of vasopressin function in health and disease. Recent Prog Horm Res 1976, 33:333-385.
74. Robertson G.L., Mahr E.A., Athar S., Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973, 52:2340-2352.
75. Robertson G.L., Shelton R.L., Athar S. The osmoregulation of vasopressin. Kidney Int 1976, 10:25-37.
76. Robertson G.L., Aycinena P., Zerbe R.L. Neurogenic disorders of osmoregulation. Am J Med 1982, 72:339-353.
77. Saito T., Ishikawa S., Abe K., et al. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997, 82:1054-1057.
78. Saito T., Ishikawa S.E., Ando F., Higashiyama M., Nagasaka S., Sasaki S. Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats. Am J Physiol 2000, 279:F502-F508.
79. Sands J.M., Flores F.X., Kato A., et al. Vasopressin-elicited water and urea permeabilities are altered in IMCD in hypercalcemic rats. Am J Physiol 1998, 274:F978-F985.
80. Schrier R.W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988, 319:1065-1072.
81. Schrier R.W. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 1988, 319:1127-1134.
82. Schrier R.W. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006, 17:1820-1832.
83. Schrier R.W., Berl T. Mechanism of effect of alpha adrenergic stimulation with norepinephrine on renal water excretion. J Clin Invest 1973, 52:502-511.
84. Schrier R.W., Gross P., Gheorghiade M., et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
85. Singer I., Rotenberg D. Demeclocycline-induced nephrogenic diabetes insipidus. In-vivo and in-vitro studies. Ann Intern Med 1973, 79:679-683.
86. Sladek C.D., Kapoor J.R. Neurotransmitter/neuropeptide interactions in the regulation of neurohypophyseal hormone release. Exp Neurol 2001, 171:200-209.
87. Soupart A., Gross P., Legros J.J., et al. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006, 1:1154-1160.
88. Szatalowicz V.L., Arnold P.E., Chaimovitz C., Bichet D., Berl T., Schrier R.W. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure. N Engl J Med 1981, 305:263-266.
89. Tahara A., Tomura Y., Wada K.I., et al. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 1997, 282:301-308.
90. Teitelbaum I., Berl T. Water metabolism in patients with electrolyte disorders. Semin Nephrol 1984, 4:354.
91. Teitelbaum I., Berl T. Effects of calcium on vasopressin-mediated cyclic adenosine monophosphate formation in cultured rat inner medullary collecting tubule cells. Evidence for the role of intracellular calcium. J Clin Invest 1986, 77:1574-1583.
92. Thurman J., Halterman R., Berl T. Therapy of dysnatremic disorder. Therapy in nephrology and hypertension 2003, 35. WB Saunders, Philadelphia. 2nd edn. H. Brady, C.S. Wilcox (Eds.).
93. Udelson J.E., Smith W.B., Hendrix G.H., et al. Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001, 104:2417-2423.
94. Udelson J.E., McGrew F.A., Flores E., et al. Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007, 49:2151-2159.
95. Verbalis J.G. Inhibitory controls of drinking. Thirst: physiological and psychological aspects 1991, Springer-Verlag, London. D.J. Ramsay, D.A. Booth (Eds.).
96. Verbalis J.G. Osmotic inhibition of neurohypophysial secretion. Ann NY Acad Sci 1993, 689:146-160.
97. Verbalis J.G. Vaptans for the treatment of hyponatremia: how, who, when and why. Nephrol Self Assess Prog 2007, 6:199-209.
98. Verney E.B. The antidiuretic hormone and the factors which determine its release. Proc R Soc Lond B Biol Sci 1947, 135:25.
99. Walker R.G. Lithium nephrotoxicity. Kidney Int Suppl 1993, 42:S93-S98.
100. Walter K.A. Conivaptan: new treatment for hyponatremia. Am J Health Syst Pharm 2007, 64:1385-1395.
101. Wang W., Li C., Summer S.N., et al. Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency. Am J Physiol 2006, 290:F1135-F1142.
102. Wong F., Blei A.T., Blendis L.M., Thuluvath P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003, 37:182-191.
103. Xu D.L., Martin P.Y., Ohara M., et al. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat. J Clin Invest 1997, 99:1500-1505.
104. Yamamura Y., Ogawa H., Yamashita H., et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992, 105:787-791.
105. Zeltser D., Rosansky S., van Rensburg H., Verbalis J.G., Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007, 27:447-457.
106. Zerbe R.L., Miller J.Z., Robertson G.L. The reproducibility and heritability of individual differences in osmoregulatory function in normal human subjects. J Lab Clin Med 1991, 117:51-59.
107. Zimmerman E.A., Ma L.Y., Nilaver G. Anatomical basis of thirst and vasopressin secretion. Kidney Int Suppl 1987, 21:S14-S19.
108. Verbalis J.G. How does the brain sense osmolality?. J Am Soc Nephrol 2007, 18:3056-3059.
109. Zaoral M., Kolc J., Sorm F. Amino acids and peptides. LXXII. Synthesis of 1-deamino-8-D-y-aminobutyrine-vasopressin, 1-deamino-8-D-lysine-vasopressin, 1-deamino-8-D-arginine-vasopressin. Coll Czech Chem Commun 1967, 32:1250-1257.